Evidence map›Paper›PMID 19656893›Full record

ArticleJournal of virology2009

Complementation of a herpes simplex virus ICP0 null mutant by varicella-zoster virus ORF61p.

Christos A Kyratsous, Matthew S Walters, Christos A Panagiotidis, Saul J Silverstein

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Varicella Zoster Virus Neuronal Latency and Reactivation Modeled in Vitro.Current topics in microbiology and immunology · 2023
    Review
  3. Article
  4. Review
  5. Glycerosome ofMolecules (Basel, Switzerland) · 2020
    Article
  6. The Fate of Speckled Protein 100 (Sp100) During Herpesviruses Infection.Frontiers in cellular and infection microbiology · 2020
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Christos A KyratsousDepartment of Microbiology, College of Physicians and Surgeons, Columbia University, 701 W. 168th St., New York, NY 10032, USA.
Matthew S Walters
Christos A Panagiotidis
Saul J Silverstein
Columbia University · USAristotle University of Thessaloniki · GR

Funding

VZ VIRUS: CLINICAL IMPLICATIONS OF IMMUNITYR01AI024021 · NIAID · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI SILVERSTEIN, SAUL J · 1986 to 2008
$3.0M
Varicella Zoster Virus:Clinical Implications of ImmunityR21AI024021 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SILVERSTEIN, SAUL J · 2003 to 2003
$363k
NIAID NIH HHS AI-024021NIAID NIH HHS R01 AI024021NIAID NIH HHS R21 AI024021
6 · The paper itself

Abstract

The herpes simplex virus (HSV) ICP0 protein acts to overcome intrinsic cellular defenses that repress viral alpha gene expression. In that vein, viruses that have mutations in ICP0's RING finger or are deleted for the gene are sensitive to interferon, as they fail to direct degradation of promyelocytic leukemia protein (PML), a component of host nuclear domain 10s. While varicella-zoster virus is also insensitive to interferon, ORF61p, its ICP0 ortholog, failed to degrade PML. A recombinant virus with each coding region of the gene for ICP0 replaced with sequences encoding ORF61p was constructed. This virus was compared to an ICP0 deletion mutant and wild-type HSV. The recombinant degraded only Sp100 and not PML and grew to higher titers than its ICP0 null parental virus, but it was sensitive to interferon, like the virus from which it was derived. This analysis permitted us to compare the activities of ICP0 and ORF61p in identical backgrounds and revealed distinct biologic roles for these proteins.

Indexed as

Gene DeletionRecombination, GeneticSimplexvirusViral ProteinsAntigens, NuclearAutoantigensCell Line, TumorGenetic Complementation TestHerpesvirus 3, HumanHumansImmediate-Early ProteinsInterferon-alphaMutationNuclear ProteinsPromyelocytic Leukemia ProteinTranscription FactorsAntigens, NuclearAutoantigensImmediate-Early ProteinsInterferon-alphaNuclear ProteinsPML protein, humanPromyelocytic Leukemia Proteinprotein 61, Varicella-zoster virusSP100 protein, humanTranscription FactorsTumor Suppressor ProteinsUbiquitin-Protein LigasesViral ProteinsVmw110 protein, Human herpesvirus 1

Identifiers

PMID19656893
PMCPMC2753114
OpenAlexW2117940640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.